BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22281725)

  • 1. Oral calcitonin.
    Maricic MJ
    Curr Osteoporos Rep; 2012 Mar; 10(1):80-5. PubMed ID: 22281725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral salmon calcitonin--pharmacology in osteoporosis.
    Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
    Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcitonin].
    Nakano T
    Clin Calcium; 2008 Oct; 18(10):1460-8. PubMed ID: 18830043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin.
    Silverman SL
    Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis.
    Bhandari KH; Asghar W; Newa M; Jamali F; Doschak MR
    Curr Drug Deliv; 2015; 12(1):98-107. PubMed ID: 25860966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
    Body JJ
    Bone; 2002 May; 30(5 Suppl):75S-79S. PubMed ID: 12008163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
    Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
    J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin therapy in osteoporosis.
    Muñoz-Torres M; Alonso G; Raya MP
    Treat Endocrinol; 2004; 3(2):117-32. PubMed ID: 15743107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of calcitonin tolerance after intramuscular or intranasal administration in treatment for postmenopausal osteoporosis].
    Horst-Sikorska W; Ruszkowska J; Kosowicz J
    Przegl Lek; 1996; 53(1):9-11. PubMed ID: 8711177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC; Rizzoli R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmon calcitonin: a review of current and future therapeutic indications.
    Chesnut CH; Azria M; Silverman S; Engelhardt M; Olson M; Mindeholm L
    Osteoporos Int; 2008 Apr; 19(4):479-91. PubMed ID: 18071651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
    Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonins and osteoporosis.
    Gennari C; Agnusdei D
    Br J Clin Pract; 1994; 48(4):196-200. PubMed ID: 7917799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
    Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
    Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.